Addressing tumor blood vessels, Nature Biotechnology, vol.92, issue.6, p.510, 1997. ,
DOI : 10.1016/S0959-8049(96)00376-0
Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, vol.55, issue.18, pp.3964-3968, 1995. ,
Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma, Cancer, vol.92, issue.2, pp.226-231, 1996. ,
DOI : 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J
Molecular determinants in the biology of liver metastasis, Surg Oncol Clin North Am, vol.5, issue.2, pp.215-229, 1996. ,
The Biology of Vascular Endothelial Growth Factor, Endocrine Reviews, vol.18, issue.1, pp.4-25, 1997. ,
DOI : 10.1210/edrv.18.1.0287
A preclinical and clinical review of aflibercept for the management of cancer, Cancer Treatment Reviews, vol.38, issue.5, pp.484-493, 2012. ,
DOI : 10.1016/j.ctrv.2011.12.008
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer, Annals of Oncology, vol.19, issue.Supplement 7, pp.91-95, 2008. ,
DOI : 10.1093/annonc/mdn473
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors, Expert Opinion on Biological Therapy, vol.108, issue.2, pp.263-271, 2009. ,
DOI : 10.1200/JCO.2007.14.7116
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors, Journal of Clinical Oncology, vol.28, issue.2, pp.207-214, 2009. ,
DOI : 10.1200/JCO.2009.22.9237
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling, AJP: Heart and Circulatory Physiology, vol.290, issue.2, 2006. ,
DOI : 10.1152/ajpheart.00616.2005
Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models, Angiogenesis, vol.79, issue.2, pp.429-441, 2012. ,
DOI : 10.1007/s10456-012-9328-3
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours, British Journal of Cancer, vol.10, issue.4, pp.598-603, 2012. ,
DOI : 10.1158/1078-0432.CCR-06-2553
Phase 1???2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer, The Lancet Oncology, vol.12, issue.12, pp.1109-1117, 2011. ,
DOI : 10.1016/S1470-2045(11)70244-3
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites, Gynecologic Oncology, vol.125, issue.1, pp.42-47, 2012. ,
DOI : 10.1016/j.ygyno.2011.11.021
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non???Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial, Journal of Clinical Oncology, vol.30, issue.29, pp.3640-3647, 2012. ,
DOI : 10.1200/JCO.2012.42.6932
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC), OncoTargets and therapy, vol.5, pp.59-65, 2012. ,
Aflibercept in the treatment of metastatic colorectal cancer, Clin Med Insights, vol.6, pp.19-30, 2012. ,
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen, Journal of Clinical Oncology, vol.30, issue.28, pp.3499-3506, 2012. ,
DOI : 10.1200/JCO.2012.42.8201
A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects, British Journal of Clinical Pharmacology, vol.37, issue.7, pp.402-414, 2011. ,
DOI : 10.1111/j.1365-2125.2011.04015.x
URL : https://hal.archives-ouvertes.fr/inserm-00629806
MONOLIX (MOdèles NOn LInéaires à effets miXtes), 2008. ,
Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1038, 2005. ,
DOI : 10.1016/j.csda.2004.07.002
The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model, Statistics in Medicine, vol.13, issue.27, pp.4860-4875, 2007. ,
DOI : 10.1002/sim.2950
URL : https://hal.archives-ouvertes.fr/hal-00263511
Tests of statistical hypotheses concerning several parameters when the number of observations is large, Transactions of the American Mathematical Society, vol.54, issue.3, pp.426-482, 1943. ,
DOI : 10.1090/S0002-9947-1943-0012401-3
Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide, Pharmaceutical Research, vol.91, issue.9, pp.2036-2049, 2006. ,
DOI : 10.1007/s11095-006-9067-5
URL : https://hal.archives-ouvertes.fr/inserm-00189557
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R, Computer Methods and Programs in Biomedicine, vol.90, issue.2, pp.154-166, 2008. ,
DOI : 10.1016/j.cmpb.2007.12.002
URL : https://hal.archives-ouvertes.fr/inserm-00274332
Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics, J Soc Fr Stat, vol.151, pp.106-128, 2010. ,
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions, The AAPS Journal, vol.11, issue.3, pp.558-569, 2009. ,
DOI : 10.1208/s12248-009-9133-0
General pharmacokinetic model for drugs exhibiting targetmediated drug disposition, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.6, pp.507-532, 2001. ,
DOI : 10.1023/A:1014414520282
Target-mediated drug disposition and dynamics, Biochemical Pharmacology, vol.72, issue.1, pp.1-10, 2006. ,
DOI : 10.1016/j.bcp.2005.12.041
Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition, Pharmaceutical Research, vol.30, issue.10, pp.1589-1596, 2005. ,
DOI : 10.1007/s11095-005-6650-0
Approximations of the target-mediated drug disposition model and identifiability of model parameters, Journal of Pharmacokinetics and Pharmacodynamics, vol.63, issue.5, pp.573-591, 2008. ,
DOI : 10.1007/s10928-008-9102-8
Target-Mediated Drug Disposition: New Derivation of the Michaelis-Menten Model, and Why It Is Often Sufficient for Description of Drugs with TMDD, PAGE, vol.19, 2010. ,
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer, British Journal of Cancer, vol.53, issue.7, pp.978-985, 2007. ,
DOI : 10.1016/j.canlet.2003.09.018
A compartment model of VEGF distribution in blood, healthy and diseased tissues, BMC Systems Biology, vol.2, issue.1, p.77, 2008. ,
DOI : 10.1186/1752-0509-2-77
Clinical pharmacokinetics of bevacizumab in patients with solid tumors, Cancer Chemotherapy and Pharmacology, vol.28, issue.5, pp.779-786, 2008. ,
DOI : 10.1007/s00280-007-0664-8
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis, European Journal of Clinical Pharmacology, vol.122, issue.4 Suppl 1, pp.1211-1228, 2009. ,
DOI : 10.1007/s00228-009-0718-4
Clinical translation of angiogenesis inhibitors, Nature Reviews Cancer, vol.17, issue.10, pp.727-739, 2002. ,
DOI : 10.1038/nrc905
Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery, The AAPS Journal, vol.12, issue.2, pp.223-232, 2010. ,
DOI : 10.1208/s12248-010-9181-5
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303), Journal of Clinical Oncology, vol.28, issue.22, pp.3617-3622, 2010. ,
DOI : 10.1200/JCO.2010.28.1386
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade, Proceedings of the National Academy of Sciences, vol.104, issue.47, pp.18363-18370, 2007. ,
DOI : 10.1073/pnas.0708865104